Press release | November 3, 2011
Delphi advises on significant pharma deal
Delphi has been legal advisor to DuoCort AB in connection with the sale of its subsidiary DuoCort Pharma AB to the NASDAQ listed biopharmaceutical company Viropharma Inc. Delphi’s team consisted of Anders Jemail (partner), Per Lagerkvist (partner) and Micael Karlsson (associate).
Just recently it was announced that Viropharma Inc. and DuoCort AB signed an agreement on the acquisition of DuoCort Pharma AB. DuoCort Pharma has developed the orphan drug Plenadren, a new treatment for adrenal insufficiency also called Addison´s disease. The deal is conditioned upon receipt of market authorization for Plenadren within EU. At closing an upfront purchase price of SEK 220 million will be paid with the possibility of additional SEK 860 million in various milestone payments.